298 results on '"Bonomi, Marcelo"'
Search Results
52. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
53. Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option
54. Adjuvant Treatment for Elderly Patients with Early-Stage Lung Cancer Treated with Limited Resection
55. Postoperative radiotherapy for elderly patients with stage III lung cancer
56. Time to Surgery and Survival in Head and Neck Cancer
57. Identification of Clinical and Socioeconomic Predictors of Adjuvant Therapy after Trans-Oral Robotic Surgery in Patients with Oropharyngeal Squamous Cell Carcinoma
58. Sinonasal undifferentiated carcinoma: Institutional trend toward induction chemotherapy followed by definitive chemoradiation
59. Emerging Concepts and Novel Strategies in Radiation Therapy for Laryngeal Cancer Management
60. Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
61. Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).
62. Effectiveness of Radiation Therapy for Elderly Patients with Unresected Stage I and II Non-Small Cell Lung Cancer
63. Radiation Therapy for the Treatment of Unresected Stage I-II Non-small Cell Lung Cancer
64. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma
65. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study
66. Reply to Topkan et al. Toxicities and prognostic factors in elderly HPV‐associated oropharyngeal cancer patients treated with radiotherapy or chemoradiotherapy.
67. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
68. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
69. Erratum: Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience
70. Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience
71. Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer
72. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
73. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients
74. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer.
75. Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience.
76. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis
77. Clinical and immune effects of cetuximab and weekly low dose carboplatin and paclitaxel in head and neck cancer patients with poor performance status.
78. Quality of life (QoL) analysis in HPV positive oropharynx cancer (HPVOPC) patients in a randomized deintensification trial.
79. Incidence of ototoxicity in head and neck cancer (HNSCC) patients (pts) receiving concomitant chemo-radiation (CRT) with weekly or triweekly cisplatin (Cis).
80. Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy
81. Immune-related saliva micro-RNA’s to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).
82. Phase 2 trial of chemotherapy followed by consolidative radiation therapy for initial treatment of oligometastatic NSCLC.
83. The Effects of smoking status and smoking history on patients with brain metastases from lung cancer
84. Human papillomavirus-related small cell carcinoma of the oropharynx: a case report and literature review
85. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.
86. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
87. Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer
88. Pilot study of first-in-class antimitochondrial metabolism agent, CPI-613, as salvage monotherapy for small cell lung cancer.
89. Measurement of Pain and Health-Related Quality of Life Measures in Adult Males with Hemophilia: Initial Observations of Disease Impact (S724)
90. Urinary Specific Gravity (USG) as an Assessment Tool for the Management of Dehydration in Head and Neck Cancer Patients Receiving Chemo-Radiation with Weekly Cisplatin
91. Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: Impact of Histology
92. Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients
93. Hydroxyurea in sickle cell patients: A look at the correlation with hematologic malignancies.
94. Hypoxia and neoplasms: Sickle cell patients as a living model.
95. Role of Human Papillomavirus and p16 Staining in a Patient With Head and Neck Cancer Presenting With a Synchronous Lung Nodule: A Case Report and Review of the Literature
96. Whole exome sequencing of sinonasal cancers.
97. Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).
98. Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).
99. Progression-free survival (PFS) as a measure of efficacy for anti-EGFR antibodies in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).
100. Abstract 4676: Metabolic reprogramming evoked by nitrosative stress enhances the effect of radiation in brain metastases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.